Home › Compare › KIARF vs MRK

KIARF vs MRK: Dividend Comparison 2026

KIARF yields 20000000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KIARF wins by $4.875981653489057e+49M in total portfolio value
10 years
KIARF
KIARF
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full KIARF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — KIARF vs MRK

📍 KIARF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKIARFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KIARF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
KIARF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KIARF
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, KIARF beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KIARF + MRK for your $10,000?

KIARF: 50%MRK: 50%
100% MRK50/50100% KIARF
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

KIARF
No analyst data
Altman Z
-5.0
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KIARF buys
0
MRK buys
0
No recent congressional trades found for KIARF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKIARFMRK
Forward yield20000000.00% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$4.875981653489057e+49M$56.8K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$9,798.13
Total dividends collected$4.875978515990276e+49M$28.9K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KIARF vs MRK ($10,000, DRIP)

YearKIARF PortfolioKIARF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$11,206$366.19+$2000.00M → KIARF
2$373,835,915,712,384$373,833,775,700,934.50$12,650$502.35+$373835915.70M → KIARF
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$14,407$694.19+$65304953364964.95M → KIARF
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$16,585$967.82+$10661728832755499008.00M → KIARF
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$19,342$1,363.89+$1.626767783781495e+24M → KIARF
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$22,913$1,947.19+$2.319743300546251e+29M → KIARF
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$27,662$2,823.89+$3.0915106403922057e+34M → KIARF
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$34,159$4,173.35+$3.8505079858392777e+39M → KIARF
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$43,337$6,308.80+$4.4821026103531426e+44M → KIARF
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$56,776$9,798.13+$4.875981653489057e+49M → KIARF

KIARF vs MRK: Complete Analysis 2026

KIARF — Stock

Kiaro Holdings Corp. owns and operates cannabis retail stores in Canada. It operates through three segments: Retail Cannabis Stores, Wholesale Cannabis Business, and eCommerce. The company offers cannabis and cannabis related products. The company also operates an eCommerce platform that offers consumption accessories in Canada, the United States, and Australia; and engages in the wholesale of cannabis products to other licensed retailers in Saskatchewan. It sells its products through a network of seventeen stores in British Columbia, Saskatchewan, and Ontario, as well as online. Kiaro Holdings Corp. is headquartered in Vancouver, Canada.

Full KIARF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this KIARF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KIARF vs SCHDKIARF vs JEPIKIARF vs OKIARF vs KOKIARF vs MAINKIARF vs JNJKIARF vs ABBVKIARF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.